

- Oxygen therapy  
 for asthma exacerbation, 1679  
 for cluster headache, 2595  
 for COPD, 1706, 1707  
 for dyspnea, 47e-4, 62  
 for high-altitude pulmonary edema, 476e-4  
 hyperbaric. *See* Hyperbaric oxygen therapy  
 for hyponatremia, 302  
 for hypothermia, 478e-2  
 for hypovolemic shock, 1748  
 for myocardial infarction, 1603  
 for pulmonary edema, 1763  
 for respiratory acidosis, 324  
 Oxygen uptake, 306e-3, 1748t  
 Oxygen uptake index, 1748t  
 Oxyhemoglobin, 632, 632f  
 Oxymetazoline, 2122  
 Oxyntic cell, 1911, 1911f  
 Oxyntic gland, 1911, 1911f  
 Oxyphenbutazone, 727t  
 Oxytocin, 2274, 2275, 2275f  
 Ozone exposure, 1692t
- P**  
 P1 syndromes, 2575  
 P2 syndromes, 2575  
 P2Y<sub>12</sub> antagonists, reversible, 749  
 P5N (pyrimidine-5'-nucleotidase) deficiency, 431e-5t, 431e-6f  
 P5N (pyrimidine-5'-nucleotidase) superactivity, 431e-5t  
 p14<sup>ARF</sup>, 102e-2, 494  
 p16/*CDKN2A* gene mutations, 554  
 p16 gene mutations, 554, 2305t  
 p16<sup>INK4a</sup>, 89e-3, 101e-6t, 102e-1, 102e-7  
 p16 protein, 494  
 p21 gene mutations, 576  
 p21 protein, 102e-1  
 p21/*WAF* gene mutations, 2305t  
 p24 antigen capture assay, 770, 771f, 1243f, 1246-1247, 1247t  
 p27 protein, 102e-1  
 p53 gene, adenoviral-mediated expression of, 91e-4  
 p53 gene mutations  
 in bladder cancer, 576  
 in breast cancer, 523, 528  
 in cancer, 101e-8, 102e-2, 102e-2f, 431t  
 in colorectal cancer, 101e-9f  
 in esophageal cancer, 533  
 in head and neck cancer, 503  
 in Li-Fraumeni syndrome, 119e-1, 599t  
 in lung cancer, 507  
 in pancreatic cancer, 554  
 in skin cancer, 387  
 in skin response to sun, 386  
 in thyroid cancer, 2304, 2305t  
 p53 protein  
 activation of, 102e-2, 102e-2f  
 in cancer cells, 102e-2, 102e-15, 372e-23, 372e-25t  
 in colon cancer, 101e-1f  
 in melanoma, 494  
 in SLE, 372e-25t  
 VEGF inhibition and, 102e-16f  
 p62, 372e-25t  
 p63, 508  
 p70S6K, 102e-4f  
 p-80-Collin, 372e-24t  
 P450 oxidoreductase deficiency, 2328t  
 PA 824, 205e-7  
 PACE (Program for All Inclusive Care of the Elderly), 82-83  
 Pacemaker, **1469**  
 for AV conduction block, 1474-1476, 1475t, 1476t  
 for bradyarrhythmia, 273e-7, 1466  
 for carotid sinus hypersensitivity, 1470  
 CMR in patient with, 270e-9  
 complications of, 816, 1469  
 five-letter codes for, 1469  
 indications for, 273e-7  
 for myocardial infarction, 1475-1476, 1475t, 1609  
 nomenclature of, 1469  
 pacing mode, 1469, 1476  
 for pulmonary edema, 1763  
 for SA node dysfunction, 1470, 1470t  
 travelers with, 799  
 for vasovagal syncope, 1470  
 Pacemaker cells, 273e-1, 273e-3, 1466  
 Pacemaker syndrome, 1469  
 Pachydermoperiostosis, 2244. *See also* Hypertrophic osteoarthropathy  
 Packed red blood cells, 138e-2, 138e-2t  
 Paclitaxel  
 action of, 103e-14-15  
 adverse effects of, 103e-12t, 103e-15  
 hypersensitivity reaction, 1798  
 lupus syndrome, 2218t  
 myopathy, 2218t  
 nail disorders, 380  
 neurologic, 1793, 2686t  
 for bladder cancer, 577  
 for breast cancer, 529, 530  
 for carcinoma of unknown primary, 120e-4  
 in drug-eluting stents, 296e-2  
 for head and neck cancer, 505  
 for lung cancer, 518t, 520t, 521t  
 for melanoma, 499  
 for ovarian cancer, 593  
 premedication for, 103e-12t, 103e-15  
 for testicular cancer, 591  
*PADI4* gene mutations, 2140  
 PAF (pure autonomic failure), 2642  
 Paget disease, extramammary, 502  
 Paget-Schroetter syndrome, 1647  
 Paget's disease of bone, **426e-1**  
 back pain in, 118  
 clinical features of, 426e-2  
 complications of, 426e-2  
 diagnosis of, 426e-2-3, 426e-2f, 426e-3f  
 epidemiology of, 426e-1  
 etiology of, 426e-1, 426e-1f  
 genetic considerations in, 426e-1  
 global considerations in, 426e-1  
 juvenile, 426e-1  
 multiple-site, 436e-3f  
 oral manifestations of, 236  
 pathophysiology of, 426e-1-2  
 of tibia, 436e-3f  
 treatment of, 426e-3-4, 426e-3t  
 PAH. *See* Pulmonary arterial hypertension (PAH)  
 PAI-1. *See* Plasminogen activator inhibitor I (PAI-1)  
 Pain  
 acute, treatment of, **90**  
 acetaminophen for. *See* Acetaminophen  
 aspirin for. *See* Aspirin  
 nonsteroidal anti-inflammatory drugs for. *See* Nonsteroidal anti-inflammatory drugs  
 opioids for. *See* Opioid(s)  
 approach to the patient, 111-114  
 assessment of, 60, 2539  
 cancer, 473-474  
 chronic, 80, **93**, 93t. *See also* Opioid(s)  
 depression and, 93  
 etiology of, 60  
 frequency of, 60  
 in MS, 2672  
 neuropathic, 60, 89-90, 94-95. *See also* Neuropathy(ies)  
 nociceptive, 60  
 pathophysiology of, **87**  
 central mechanisms, 88-89, 89f  
 neuropathic pain, 89-90  
 pain modulation, 89, 90f, 91f  
 peripheral mechanisms, 87-88, 87f, 88f  
 perception of, 107  
 psychological variables, 93  
 racial/ethnic disparities in treatment of, 16e-1  
 referred. *See* Referred pain  
 sympathetically maintained, 90  
 in terminally ill patient, 60-61  
 testing sense of, 159, 160t  
 visceral, 60  
 Painful articular syndrome, 1261  
 Painless (silent) thyroiditis, 2299  
 Palatal tremor, 41e-1v  
*PALB2* gene mutations, 554  
 Palifermin, for mucositis, 103e-25, 139e-3  
 Palilalia, 177, 2623  
 Paliperidone, 2721, 2722t  
 Palivizumab, 1206  
 Palla's sign, 1633  
 Palliative care, **56**. *See also* End-of-life care  
 for cancer, 103e-3, 103e-7, 472, **473**  
 insurance coverage of, 70  
 for non-hospice patient, 70  
 Pallister-Hall syndrome, 2264  
 Pallister-Killian syndrome, 83e-6  
 Palmar crease, 393, 1442  
 Palmar erythema, 1992, 2058, 2059f  
 Palmar fasciitis, 2247  
 Palmonal response, 2539  
 Palonosetron, 62, 103e-25, 261  
 Palpation  
 of abdomen, 106  
 of chest, 1662  
 of heart, 1447  
 of spleen, 411  
 Palpitations, **254**  
 approach to the patient, 254  
 in arrhythmia, 254, 273e-5  
 in atrial fibrillation, 254  
 etiology of, 254  
 treatment of, 254  
 Palsy(ies)  
 Bell's. *See* Bell's palsy  
 cranial nerve. *See* Cranial nerve disorders  
 2-PAM Cl (2-pralidoxime chloride), for nerve agent exposure, 262e-5t, 262e-6, 262e-6f  
 Pamidronate  
 for bone pain, 61  
 for hypercalcemia, 314, 610, 2480t, 2481  
 for metastatic bone disease, 119e-4  
 for multiple myeloma, 717  
 for Paget's disease of bone, 426e-3-4, 426e-3t  
 PAMPs (pathogen-associated molecular patterns), 145e-5, 145e-8f, 372e-2, 1747  
 Pan American Sanitary Bureau, 8  
 pANCA (perinuclear ANCA), 2180  
 Pancoast tumor  
 in lung cancer, 510  
 neck pain in, 123  
 shoulder pain in, 2221  
 treatment of, 519  
 Pancreas  
 annular, 2102  
 beta cells of, 2403-2404  
 biopsy of, 2087t, 2089  
 disorders of. *See* Pancreatic disease  
 exocrine secretion in, **2090**  
 in autoprotection of pancreas, 2091  
 enteropancreatic axis and feedback inhibition in, 2091  
 enzymes in, 2090-2091  
 insufficient, 2098, 2098t. *See also* Chronic pancreatitis  
 laboratory evaluation of, 2087t, 2090  
 regulation of, 2090  
 in steatorrhea, 1940  
 water and electrolyte content of, 2090  
 fluid volumes and electrolyte content of, 98e-4t  
 transplantation, 928, 2417, 2433  
 Pancreas divisum, 2102  
 Pancreatotomy, 2101  
 Pancreatic agenesis, 431t  
 Pancreatic cancer, **554**  
 clinical features of, 366, 554-555  
 deaths from, 467t, 468f, 470t  
 diagnosis of, 555, 555f  
 epidemiology of, 554  
 extrahepatic cholestasis in, 285  
 gastroparesis in, 259  
 genetic considerations in, 101e-2t, 102e-7, 554  
 global considerations in, 554  
 incidence of, 467t